Gilead Sciences, Inc. $GILD Shares Acquired by Compound Planning Inc.

Key Points

• Compound Planning Inc. increased its position in Gilead Sciences by 179.0% during the first quarter, bringing its total shares to 23,193, valued at $2.6 million.
• Gilead Sciences reported an earnings per share (EPS) of $2.01 for the last quarter, beating estimates by $0.05, with revenues reaching $7.08 billion.
• The company announced a quarterly dividend of $0.79, representing an annual yield of 2.8%, to be paid on September 29th to shareholders of record as of September 15th.

Compound Planning Inc. grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 179.0% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 23,193 shares of the biopharmaceutical company's stock after buying an additional 14,881 shares during the quarter. Compound Planning Inc.'s holdings in Gilead Sciences were worth $2,599,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Nissay Asset Management Corp Japan ADV lifted its stake in Gilead Sciences by 5.2% during the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock worth $26,750,000 after purchasing an additional 14,009 shares during the last quarter. Golden State Wealth Management LLC increased its position in Gilead Sciences by 14.5% during the first quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock worth $97,000 after buying an additional 109 shares during the period. Mufg Securities Americas Inc. acquired a new position in Gilead Sciences during the fourth quarter worth approximately $1,699,000. ASR Vermogensbeheer N.V. acquired a new position in Gilead Sciences during the first quarter worth approximately $11,688,000. Finally, Wealth Enhancement Advisory Services LLC increased its position in Gilead Sciences by 4.7% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 292,966 shares of the biopharmaceutical company's stock worth $32,827,000 after buying an additional 13,194 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Trading Down 0.5%

Gilead Sciences stock traded down $0.62 during trading on Monday, hitting $114.15. The company's stock had a trading volume of 3,812,165 shares, compared to its average volume of 6,667,523. The stock has a market capitalization of $141.64 billion, a price-to-earnings ratio of 22.74, a P/E/G ratio of 0.70 and a beta of 0.33. The stock's fifty day moving average is $112.57 and its 200 day moving average is $109.28. Gilead Sciences, Inc. has a 1-year low of $76.42 and a 1-year high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm's revenue was up 1.4% on a year-over-year basis. During the same period in the prior year, the firm posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.79 per share. The ex-dividend date is Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.8%. Gilead Sciences's dividend payout ratio is currently 62.95%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the completion of the sale, the chief executive officer directly owned 605,725 shares in the company, valued at $69,016,306.50. This represents a 1.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the sale, the insider owned 114,168 shares of the company's stock, valued at $13,532,333.04. This represents a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 82,000 shares of company stock valued at $9,339,230. Insiders own 0.27% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on GILD. UBS Group boosted their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a report on Friday, August 8th. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price on the stock in a report on Tuesday, August 19th. Daiwa America upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Truist Financial upgraded Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price target for the company from $108.00 to $127.00 in a research note on Friday, August 8th. Finally, Royal Bank Of Canada lifted their price target on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research note on Friday, August 8th. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $115.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.